Endocannabinoids are arachidonic acid derivatives and part of a novel bioactive lipid signaling system, along with their G-coupled receptors (CB 1 and CB 2 ) and the enzymes involved in their biosynthesis and degradation. However, their roles in hematopoiesis and hematopoietic stem and progenitor cell (HSPC) functions are not well characterized. Here, we show that bone marrow stromal cells express endocannabinoids, (anandamide and 2-arachidonylglycerol), while CB 2 receptors are expressed in human and murine HSPCs. Upon ligand stimulation with CB 2 agonists, CB 2 receptors induced chemotaxis, migration and enhanced colony formation of bone marrow cells, which were mediated via ERK, PI3-kinase and Gαi-Rac1 pathways. In vivo, the CB 2 agonist AM1241 induced mobilization of murine HSPCs with short-and long-term repopulating abilities. In addition, G-CSF-induced mobilization of HSPCs was significantly decreased by specific CB 2 antagonists and was impaired in Cnr2 -/-cannabinoid type 2 receptor knockout mice.
Introduction
Endocannabinoids and exogenous cannabinoid ligands bind to and activate the cannabinoid receptors CB 1 and CB 2 (1-3). Endocannabinoids are endogenous lipid mediators generated by many cell types both in the brain and peripheral tissues, which exert broad range of biological effects such as cardiovascular, neurological and anti-inflammatory effects (4) . Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are the two most widely studied endocannabinoids.
The endocannabinoid system represents a pivotal neuroprotective mechanism both in acute forms of neuronal injury (such a stroke and traumatic brain injury) and chronic neurodegenerative disorders (4) (5) (6) (7) (8) . The synthetic and natural ligands of cannabinoid receptors exert various anti-inflammatory and neuroprotective effects by several mechanisms that include receptor antagonist AM630 and the CB 1 receptor antagonist AM251 were purchased from Tocris (Ellisville, MO). G-CSF (Neupogen) was obtained from Amgen Inc. (Thousand Oaks, CA). placed onto the filters of the Transwell using a 5-µm thick polyvinylpyrrolidone-free poly-carbonate filters. Cells were seeded in the upper wells while medium containing cannabinoid agonists were added to the lower wells: CP55940 (10 nM), JWH133 (10nM) CXCL12 (100 ng/ml) or AM1241 (10 nM). Agonist, antagonist and inhibitors were added to the upper chambers as indicated. Cells were allowed to migrate for 4 h at 37°C in a humidified atmosphere with 5% CO 2 . Filters were then removed from the chambers and stained with Diff.
Cells
Quick (Baxter.) Each condition was performed in triplicate.
Mobilization of bone marrow HSPCs
For in vivo mobilization experiments, mice received: G-CSF (125 μg/kg) i.p. twice daily (morning and evening) for 4 consecutive days. The cannabinoid ligands were dissolved in
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From ethanol/cremophor/saline (1:1:18) vehicle and were administered i.p. once daily (in the morning) for four consecutive days: CP55940, JWH133, AM1241 (all ligands at a dose of 10 mg/kg) either alone or in the presence of cannabinoid receptor CB 2 antagonist AM630 (5 mg/kg), as indicated. Twenty-four hours following the last injection, mice were sacrificed; dissected and peripheral blood was collected by heart puncture. Control mice received i.p. injections of vehicle alone once daily for 4 days, (administered in the morning), and twenty-four hours following the last injection, mice were sacrificed, dissected, and peripheral blood was collected by heart puncture. Effects due to circadian regulation were controlled by restricting experimental procedures to morning schedule. White blood cells (WBC) (0.6 ml from each mice) were isolated by Ficoll separation. Briefly, blood was diluted to 6 ml and was overlaid on the 5 ml Ficoll layer. Tubes were centrifuged at 2000 rpm at 18°C for 30 min. The top layer was removed slowly with a Pasteur pipette and the WBC layer was transferred into 8-9 ml DPBS + (DPBS + containing 2% FBS) in a 15 ml conical tube. Tubes were spun at 1500 rpm at 4°C for 5 to 7 min and then the pellet was resuspended in DPBS + . The PBCs cells were collected and used for the colony-formation assays using MethoCult media, as detailed below.
Colony Formation assays
PBCs (1x 10 5 cells/ml) were cultured in MethoCult GF M3434 (Stem Cell Technologies, Vancouver, BC, Canada) containing a cocktail of cytokines to enumerate colony-forming unit granulocyte-macrophage (CFU-GM), CFU-GEMM(granulocyte-erythrocyte-monocyte-megakar yocyte),CFU-E (erythrocyte), and burst forming unit erythrocyte (BFU-E). Cultures were
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Total colonies per ml blood were determined by multiplying the CFU frequencies by the number of low-density cells per ml blood. Triplicate assays were performed for each sample. Following the incubation period, the numbers of colonies were determined by light microscopy. Positive colonies were scored on the basis of an accumulation of 40 or more cells. For human colony cultures, we employed MethoCult methylcellulose based assays (Stem Cell Technologies), based on the protocol provided by the company.
Murine transplantation assays
Transplantation assays were performed using the Ly5 congenic mouse system. Nine mice were included in each experimental group. 8 × 10 5 mobilized cells from B6-Ly5.2 mice were mixed with 2 × 10 5 BM cells from B6-Ly5.1 and were transplanted into lethally irradiated B6-Ly5.1 (950 rads) mice. Long-term engraftment was determined 20 weeks after transplantation by analyzing peripheral blood and bone marrow by flow cytometry. Cells were stained with a mixture of biothinylated anti-Ly5.1, allophycocyanin (APC)-conjugated anti-Ly5.2, FITC-conjugated anti-CD4, FITC-conjugated anti-CD8, PE-conjugated anti-Gr1, PE-conjugated anti-mac1, and APC-Cy7-conjugated anti-B220 (BD Bioscience). Secondary staining was performed using PE-Cy7-streptavidine. Flow cytometry analysis was performed on a BD LSRII cell analyzer (BD Bioscience), and data was analyzed by FlowJo 7.2.4 software.
For
Statistical analysis
The results are presented as the mean ± SD. The statistical significance of the results reported hereby was determined by a two-tailed t test. P < 0.01 and P < 0.05 were considered significant, as indicated.
Results

Expression of endocannabinoids in bone marrow-stromal cells
To study the role of the endocannabinoid system in bone marrow (BM)-stromal cells, we examined the expression of endocannabinoids, 2-AG and AEA in BM-stromal cells. As shown in Table 1 , both 2-AG and AEA were detected with AEA at 35.2pg/10 7 cells and 2-AG at 75.2ng/10 7 cells. The expression levels of AEA and 2-AG in BM stromal cells is similar to those reported in brain (37), a major organ for synthesis of endocannabinoids. In response to the stress inducer endotoxin (LPS), the expression levels of both 2-AG and AEA were increased (Table 1) .
Interestingly, LPS induced-mobilization of HSPCs, which was impaired in Cnr2 -/-mice (Table 2) .
Thus, these results suggest that BM stromal cells express endocannabinoids, which are upregulated following an immune challenge. Increased endocannabinoids may facilitate the release of HSPCs from the BM niches to the peripheral blood circulation for repopulation of hematopoiesis.
CB2 receptors are expressed on human and murine HSPCs
Next, we assess the expression of CB 2 in human and murine HSPCs . Using human CB 2 specific
antibodies we analyzed the cell surface expression of cannabinoid receptors on human BM 
Cannabinoid ligands induce colony formation and migration of human and murine HSPCs in vitro
To study the direct actions of cannabinoids on HSPCs, we first assessed the effects of various cannabinoid compounds on colony formation by human and murine bone marrow-derived cells in vitro. Treatment of human MNCs cells with CB 2 -specific agonist JWH133 or with CP55940, a ligand for both CB 1 and CB 2 , yielded a significant increase in colony numbers as compared to control non-stimulated cells (Fig. 3A) . Similarly, treatment of WT murine bone marrow cells with CP55940 or JWH133, yielded an increase in colony number (Fig. 3B) Table 1 ). Treatment of WT mice with CP55940 for up to 4 hours resulted in modest increase in the number of hematopoietic colonies (Supplemental Figure 1) , indicating that short term
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From mobilization by cannabinoids is not effective. Regarding response timeline, the short term exposure of HSPCs to CB 2 agonists produced similar, although less pronounced effects as those observed with AMD3100 (for 2-3 hrs only) (data not shown). Further, no significant effects on HSPC mobilization was observed when G-CSF was administered twice daily for 4 days followed by CB 2 agonist administration at day 5 for 2 hr, as compared to G-CSF alone (data not shown).
Treatment of WT mice with either JWH133 (CB 2 specific) or CP55940 daily for 4 days resulted in a significant (P < 0.01) increase in the number of hematopoietic colonies in peripheral blood ( Fig. 4A) Table 2 ).
CB 2 inhibition impaired G-CSF induced mobilization of HSPCs
Next, we investigated whether CB 2 could modulate G-CSF-induced mobilization. In a model involving G-CSF, a significant reduction in the number of G-CSF-induced HSPC-derived colonies was observed following the administration of CB 2 (AM630) receptor antagonists ( Fig.   4C ). Similarly, Cnr2 -/-mice showed a significant reduction of HSPCs-derived colonies upon G-CSF treatment. Since the effects in the knockout mice may not represent the full assessment due to potential compensation by the other cannabinoid receptor, we treated Cnr2 -/-knockout mouse with the CB 1 receptor antagonist for the other cannabinoid receptor. In Cnr2 -/-mice treated with G-CSF plus AM251 (CB 1 antagonist), the HSC mobilization was markedly reduced as compared to the G-CSF only treated mice (Fig. 4D ).
The Cannabinoid receptor CB 2 agonist AM1241 induces mobilization of LT-HSC in vivo
To assess if stimulation of CB 2 by AM1241 is capable of mobilizing early progenitors as well as the long-term (LT) repopulating cells, we used the CAFC assay. First we determined that 10 mg/kg of AM1241 as the optimal dose for mobilization of HSPCs in vivo (Fig. 5A ). Table S3 ). None of the vehicle-mobilized transplanted mice reconstituted all three lineages with Ly5.2 cells.
Interestingly, the effect of AM1241 in HSC mobilization, engraftment and reconstitution was similar to that observed by G-CSF ( Fig. 5C and Table S3 ). In conclusion, our data strongly suggest that the cannabinoid agonist AM1241 induces mobilization of LT-HSCs, which retain transplantation characteristics.
Cannabinoids induce HSPC migration and mobilization via and Gαi-Rac1 pathways
To elucidate the signaling pathways by which the CB 2 agonists can induce HSPC migration and mobilization, we performed chemotaxis assays. First, we demonstrated that CP55940 and For personal use only. on November 16, 2017. by guest www.bloodjournal.org From 6B, AM1241 induced Rac1 activation, which was inhibited by PTX inhibitor. Thus, based on these results, AM1241-induced HSPC migration via Gαi-Rac1 pathway.
To further address the mechanism by which cannabinoids induce mobilization of HSPCs, we examined the effects of AM1241 on CXCL12-mediated migration of HSPCs. We observed that CXCL12-induced migration of CD34 + cells (Fig. 6C ) and LSK cells ( Fig. 6D ) was inhibited by CP55940, suggesting that cannabinoid stimulation may interfere with the CXCL12-induced migration. We also assessed the combinatory effects of AM1241 and AMD3100 (a specific inhibitor of CXCR4) in HSPC mobilization in vivo. As shown in Fig. 6E , the combination of AM1241+AMD3100 significantly enhanced HSPC mobilization, suggesting a "cross-talk" between CB 2 and CXCR4. However, when we assessed if CB 2 agonist stimulation resulted in changes in CXCR4 expression in HSCs, no significant differences were observed in CXCR4 expression in HSCs mobilized by CB 2 agonist (data not shown).
Next, we evaluated whether AM1241 competed with SDF1α for binding to CXCR4, 
Discussion
The physiological balance between self-renewal and differentiation is essential for HSC function and hematopoiesis. In this report, we provide evidence that endocannabinoids are expressed in The endocannabinoid system participates in neuroendocrine control of homeostasis (6) .
Endocannabinoids are involved in the innate immune response and in homeostasis maintenance (5) . Further, the anti-inflammatory actions of endocannabinoids represent a pivotal protective mechanism both in acute and chronic disorders such as in neurodegenerative diseases (7) (8) .
Marked increase of endocannabinoid production (AEA and 2-AG) was reported in various However, there is some degree of variability in the responsiveness of normal donors and patients to the HSC-mobilizing effects of G-CSF. Here, we demonstrate that inhibition of CB 2 receptors resulted in inhibition of G-CSF-induced HSPC mobilization (Fig. 4C) . Further, G-CSF-induced-mobilization of HSPCs was significantly decreased in Cnr2 -/-mice (Fig. 4D ).
These observations suggest that the CB 2 (Fig.5) . CB 2 agonist AM1241 induced HSPC frequency similar to those obtained with G-CSF in a 20 week period (Fig. 5) . CB 2 Gαs was found to govern specific aspects of HSC localization and engraftment to the BM (28).
In addition, Prostaglandin E2-Prostaglandin receptors and adrenergic receptors were also
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From reported to enhance stem cell transplantation in mice (29). Here, we show that the CB 2 receptor, a component of the endocannabinoid system, and its specific agonists are also important in stem cell transplantation (Fig.5) . Thus, identification of additional physiological systems that can increase homing efficiency and/or increase the nurturing capacity of the niche or increase the number of cells that can be mobilized for in vivo transplantation is crucial for HSPCs based therapies. Pharmacological intervention targeted towards the endocannabinoid system could represent a novel modality for HSPC-based therapies in patients.
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